Evidence map›Paper›PMID 38473367›Full record

ArticleCancers2024

Proton Treatment Suppresses Exosome Production in Head and Neck Squamous Cell Carcinoma.

Ameet A Chimote, Maria A Lehn, Jay Bhati, Anthony E Mascia, Mathieu Sertorio, Michael A Lamba, Dan Ionascu, Alice L Tang, Scott M Langevin, Marat V Khodoun and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Motion-based tissueClinical and translational radiation oncology · 2026
    Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ameet A ChimoteDivision of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.ORCID 0000-0001-5163-0123
Maria A LehnDivision of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.ORCID 0000-0001-8400-7733
Jay BhatiDivision of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Anthony E MasciaDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Mathieu SertorioDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.ORCID 0000-0002-9395-2718
Michael A LambaDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Dan IonascuDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Alice L TangDepartment of Otolarynogology, Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Scott M LangevinLarner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Marat V KhodounDivision of Rheumatology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Trisha M Wise-DraperDivision of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Laura ConfortiDivision of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.ORCID 0000-0002-3761-7595
University of Cincinnati · USUniversity of Cincinnati Medical Center · USCincinnati Children's Hospital Medical Center · USUniversity of Vermont · US

Funding

Liposome-based mRNA cancer immunotherapy targeting ion channelsR21CA277341 · NCI · UNIVERSITY OF CINCINNATI · PI CONFORTI, LAURA · 2023 to 2024
$405k
NCI NIH HHS R21 CA277341NIH HHS 5 R21 CA 277341-02
6 · The paper itself

Abstract

Proton therapy (PT) is emerging as an effective and less toxic alternative to conventional X-ray-based photon therapy (XRT) for patients with advanced head and neck squamous cell carcinomas (HNSCCs) owing to its clustered dose deposition dosimetric characteristics. For optimal efficacy, cancer therapies, including PT, must elicit a robust anti-tumor response by effector and cytotoxic immune cells in the tumor microenvironment (TME). While tumor-derived exosomes contribute to immune cell suppression in the TME, information on the effects of PT on exosomes and anti-tumor immune responses in HNSCC is not known. In this study, we generated primary HNSCC cells from tumors resected from HNSCC patients, irradiated them with 5 Gy PT or XRT, and isolated exosomes from cell culture supernatants. HNSCC cells exposed to PT produced 75% fewer exosomes than XRT- and non-irradiated HNSCC cells. This effect persisted in proton-irradiated cells for up to five days. Furthermore, we observed that exosomes from proton-irradiated cells were identical in morphology and immunosuppressive effects (suppression of IFN-γ release by peripheral blood mononuclear cells) to those of photon-irradiated cells. Our results suggest that PT limits the suppressive effect of exosomes on cancer immune surveillance by reducing the production of exosomes that can inhibit immune cell function.

Indexed as

cancer immunologyexosomeshead and neck cancersHNSCCIFN-γphoton therapyproton therapyradiation therapy

Identifiers

PMID38473367
PMCPMC10931005
OpenAlexW4392295191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.